PolyPid Stock

PolyPid Forward P/E

The Forward P/E Ratio of PolyPid (PYPD) as of Aug 4, 2026 is -2.06. In the previous year, Forward P/E Ratio was -2.43 — a change of -15.06% (higher).

Forward P/E

-2.06

YoY

-15.06%

Last updated:

Forward P/E Ratio of PolyPid is 2026 -2.06 . Forward P/E Ratio of PolyPid was 2025 -2.43 . It decreases by -15.06% higher compared to the previous year.
Access this data via the Eulerpool API

PolyPid Stock analysis

What does PolyPid do? PolyPid Ltd is an innovative, emerging company in the field of biomedical technology based in Israel. The company was founded in 2008 and has since gained continuous recognition and growth. PolyPid's core business is the development and manufacturing of implantable polymer systems that contribute to wound healing. These polymer systems are specifically introduced into the affected area of the body and continuously release active substances to prevent infections and promote natural healing processes. PolyPid's business model is focused on effectively solving patients' problems. The company has developed a wide range of products and technologies that specifically target various medical applications. These include orthopedics, traumatology, urology, and gynecology. For orthopedics, PolyPid provides various products and technologies that can be used in knee and hip joint surgeries. These include antibiotic-releasing implants to prevent infections and resorbable bone fillers that allow for faster and more effective wound healing. In the field of traumatology, PolyPid manufactures polymer systems that are used in the treatment of bone fractures or other traumas. Here again, the polymer systems ensure continuous release of active substances to prevent infections and promote natural healing processes. PolyPid also offers innovative solutions for urology. Specifically, products are developed to combat urinary tract infections and promote faster wound healing after urological surgeries. For gynecology, PolyPid offers polymer systems that can be used particularly in the postoperative phase to prevent infections and achieve faster wound healing. PolyPid has earned an excellent reputation in the industry in recent years due to its consistent focus on innovation and quality. To continually improve their products, the company invests heavily in research and development and maintains close contact with medical institutions and professionals worldwide. PolyPid is an important partner in the field of biomedical technology and has already received numerous awards for its groundbreaking products and developments. Thanks to its focus on quality, reliability, and innovation, the company will continue to play a key role in the biomedical technology market. PolyPid is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PolyPid stock

Forward P/E Ratio of PolyPid is -2.06 in 2026.

Forward P/E Ratio of PolyPid changed from -2.43 to -2.06, representing a -15.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio PolyPid since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's PolyPid with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — PolyPid

All Key Metrics — PolyPid